Macugen News
Most Popular Macugen Story
OSI looks to unload Macugen, exit eye diseases
Just a year after buying Macugen from Eyetech (a 2003 Fierce 15 company), OSI Pharmaceuticals is looking for a way out of the eye disease sector. The company reports that it is exploring licensing or selling Macugen and its research assets in the field. Analysts expect OSI to shift its attention to its pipeline, which includes a promising therapy for …
... Read more...Latest Headlines
- January 4, 2007
- November 6, 2006
- October 29, 2006
- July 2, 2006
- February 28, 2006
- November 10, 2005
- September 6, 2005
- August 31, 2005
- August 21, 2005
- June 21, 2005
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
